ArticlePharmacoEconomics2019
The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood.
Article in PharmacoEconomics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 7 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Natalizumab and Tyruko (natalizumab biosimilar) for treating highly active relapsing-remitting multiple sclerosis after at least one disease-modifying therapy: a systematic review and economic model.Health technology assessment (Winchester, England) · 2026Pooled it
- A Systematic Review of Microsimulation Models in Cardiometabolic Disease: Model Calibration and Validation.Applied health economics and health policy · 2026Pooled it
- A scoping review of decision analytic model-based economic evaluations in neonatal intensive care.Pediatric research · 2026Pooled it
- Global Long-Term Cost Effectiveness of Newer Antidiabetic Drugs for Type 2 Diabetes Mellitus: A Systematic Review.Clinical drug investigation · 2026Pooled it
- Evaluating the Cost-Utility of Continuous Glucose Monitoring in Individuals with Type 1 Diabetes: A Systematic Review of the Methods and Quality of Studies Using Decision Models or Empirical Data.PharmacoEconomics · 2024Pooled it
- A Systematic Review of Economic Models Across the Entire Schizophrenia Pathway.PharmacoEconomics · 2020Pooled it
- Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements.PharmacoEconomics · 2020Pooled it
- The cost-effectiveness of a cash-based transfer, specialised nutritious food, and social and behaviour change communication intervention package to prevent undernutrition among children 6-23 months in Pakistan: A cluster randomised controlled trial.Journal of global health · 2024Trial
- Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management.PharmacoEconomics · 2024Article
- Evaluating the Validation Process: Embracing Complexity and Transparency in Health Economic Modelling.PharmacoEconomics · 2024Article
- A structured process for the validation of a decision-analytic model: application to a cost-effectiveness model for risk-stratified national breast screening.Applied health economics and health policy · 2024Article
- Projected health and economic impacts of sugar-sweetened beverage taxation in Germany: A cross-validation modelling study.PLoS medicine · 2023Article
- Prediction of complications in health economic models of type 2 diabetes: a review of methods used.Acta diabetologica · 2023Review
- Estimating the impact of nutrition and physical activity policies with quasi-experimental methods and simulation modelling: an integrative review of methods, challenges and synergies.European journal of public health · 2022Review
- Developing an Online Infrastructure to Enhance Model Accessibility and Validation: The Peer Models Network.PharmacoEconomics · 2022Article
- Exploring Structural Uncertainty and Impact of Health State Utility Values on Lifetime Outcomes in Diabetes Economic Simulation Models: Findings from the Ninth Mount Hood Diabetes Quality-of-Life Challenge.Medical decision making : an international journal of the Society for Medical Decision Making · 2022Article
- Optimizing diabetes screening frequencies for at-risk groups.Health care management science · 2022Article
- A meta-epidemiological assessment of transparency indicators of infectious disease models.PloS one · 2022Article
- Simulation Modeling for the Economic Evaluation of Population-Based Dietary Policies: A Systematic Scoping Review.Advances in nutrition (Bethesda, Md.) · 2021Article
- Putting Stakeholder Engagement at the Center of Health Economic Modeling for Health Technology Assessment in the United States.PharmacoEconomics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 10 institutions in 6 countries.
Funding
Abstract
Transparency in health economic decision modelling is important for engendering confidence in the models and in the reliability of model-based cost-effectiveness analyses. The Mount Hood Diabetes Challenge Network has taken a lead in promoting transparency through validation with biennial conferences in which diabetes modelling groups meet to compare simulated outcomes of pre-specified scenarios often based on the results of pivotal clinical trials. Model registration is a potential method for promoting transparency, while also reducing the duplication of effort. An important network initiative is the ongoing construction of a diabetes model registry (https://www.mthooddiabeteschallenge.com). Following the 2012 International Society for Pharmacoeconomics and Outcomes Research and the Society of Medical Decision Making (ISPOR-SMDM) guidelines, we recommend that modelling groups provide technical and non-technical documentation sufficient to enable model reproduction, but not necessarily provide the model code. We also request that modelling groups upload documentation on the methods and outcomes of validation efforts, and run reference case simulations so that model outcomes can be compared. In this paper, we discuss conflicting definitions of transparency in health economic modelling, and describe the ongoing development of a registry of economic models for diabetes through the Mount Hood Diabetes Challenge Network, its objectives and potential further developments, and highlight the challenges in its construction and maintenance. The support of key stakeholders such as decision-making bodies and journals is key to ensuring the success of this and other registries. In the absence of public funding, the development of a network of modellers is of huge value in enhancing transparency, whether through registries or other means.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.